Novartis reported Phase 3 VAYHIT2 results showing ianalumab plus eltrombopag (Promacta) significantly extended disease control in immune thrombocytopenia (ITP). The higher ianalumab dose reduced risk of treatment failure by 45% and produced a median time to failure of 13 months versus 4.7 months for placebo plus eltrombopag. The trial enrolled 152 patients and used a short four‑month infusion regimen of ianalumab aimed at depleting autoreactive B cells through BAFF‑receptor targeting. Investigators reported similar adverse event rates across arms and only one severe event related to the antibody. Authors and presenters framed the data as evidence that a limited‑course biologic can provide durable responses and potentially reduce long‑term therapy needs for ITP patients, which could reshape clinical management and commercial positioning for the asset.